- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05075083
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and Chronic Obstructive Pulmonary Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease were recruited to receive the schedule of two doses inactivated COVID-19 vaccine with the interval of 21 days .
Blood samples will be collected 2 times: before the 1st dose of vaccinatioin and 28 days after the 2nd dose of vaccination.
Any local or systemic adverse events that occurred within 21 days after vaccination will be recorded.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310051
- Recruiting
- Zhejiang Provincial Center for Disease Control and Prevention
-
Contact:
- Hanqing He
- Phone Number: +86-571-87115170
- Email: hanqinghe@cdc.zi.cn
-
Contact:
- Huakun Lv
- Phone Number: +86-571-87115111
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Subjects aged 60 and above with full capacity for civil conduct;
- Chronic bronchitis (or chronic obstructive pulmonary disease) diagnosed by a medical institution at level I or above;
- Body temperature < 37.3 ° C confirmed by clinical examination before enrollment ;
- Able and willing to complete the entire study plan during the study follow-up period;
- Have the ability to understand the study procedures, voluntarily sign informed consent, and comply with the requirements of the clinical study protocol
Exclusion criteria for the first dose:
- Subjects were previously confirmed cases of COVID-19 or asymptomatic infected persons;
- Subjects have history of vaccination against COVID-19;
- Being allergic to any component of vaccines (including excipients) ;
- Injection of non-specific immunoglobulin within 1 month before enrollment;
- Injection of live attenuated vaccines within 1 month and injection of other vaccines within 14 days before enrollment;
- Subjects who have experienced severe allergic reactions to vaccines (e.g. acute anaphylaxis, urticaria, angioneurotic edema, dyspnea, etc.);
- Having uncontrolled epilepsy and other progressive neurological disorders and a history of Guillain-Barre syndrome;
- Having severe liver and kidney diseases, malignant tumors, acute diseases or acute episodes of chronic diseases;
- Have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukaemia or other autoimmune diseases;
- Have been diagnosed with thrombocytopenia or other clotting disorders that may contraindicate subcutaneous injection;
- During an acute episode of chronic bronchitis/chronic obstructive pulmonary disease;
- Other subjects whose physical conditions, as determined by the investigator, are not suitable for inclusion in clinical studies.
Exclusion criteria for the second dose:
- Subjects who had vaccine-related adverse reactions after the first dose;
- Having high fever (axillary temperature ≥39.0℃) for three days after the first dose of inoculation, or severe allergic reaction;
- Having any adverse nervous system reaction after the first dose;
- During the acute onset of a chronic disease, or the recovery of acute complications less than two weeks;
- Other reasons for exclusion considered by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental Group
A total 400 subjects receive two doses inactivated COVID-19 vaccine with the interval of 21 days
|
receive two doses inactivated COVID-19 vaccine with the interval of 21 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline neutralizing antibody level
Time Frame: Before vaccination (Day 0)
|
Neutralizing antibody geometric mean titer(GMT) against coronavirus before vaccination
|
Before vaccination (Day 0)
|
Neutralizing antibody level
Time Frame: 28 days after the 2th dose (Day 49)
|
Neutralizing antibody GMT against coronavirus after the 2th dose
|
28 days after the 2th dose (Day 49)
|
Seroconversion rate
Time Frame: 28 days after the 2th dose (Day 49)
|
The rate of seroconversion against coronavirus
|
28 days after the 2th dose (Day 49)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serious adverse event rate
Time Frame: 0-6 months
|
Report and analyse serious adverse events
|
0-6 months
|
Adverse events rate
Time Frame: 0-21days following vaccinations
|
Analyse the incidence of adverse events following vaccination, both solicited and unsolicited
|
0-21days following vaccinations
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- Bronchial Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- COVID-19
- Acute Disease
- Bronchitis
- Bronchitis, Chronic
Other Study ID Numbers
- BIBP2021COPD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Inactivated COVID-19 vaccine
-
China National Biotec Group Company LimitedThe University of Hong Kong; Beijing Institute of Biological Products Co Ltd.; Wuhan Institute of Biological Products Co., LtdActive, not recruiting
-
China National Biotec Group Company LimitedWuhan Institute of Biological Products Co., Ltd; Hubei Provincial Center for...RecruitingHIV Infections | COVID-19China
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.; Zhejiang Provincial Center...Not yet recruitingHIV Infections | COVID-19China
-
China National Biotec Group Company LimitedWuhan Institute of Biological Products Co., Ltd; Hubei Provincial Center for...RecruitingCOVID-19 | Copd | Chronic BronchitisChina
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.; Zhejiang Provincial Center...RecruitingHIV Infections | COVID-19China
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.; Zhejiang Provincial Center...Not yet recruitingCOVID-19 | COPD | Chronic BronchitisChina
-
Butantan InstituteCompletedSARS-CoV-2 Acute Respiratory DiseaseBrazil
-
Sinovac Research and Development Co., Ltd.CompletedCOVID-19Dominican Republic
-
Bozyaka Training and Research HospitalCompleted
-
WestVac Biopharma Co., Ltd.Active, not recruitingCOVID-19 | SARS-CoV-2 InfectionMexico